



Members of the Nomination Committee for Episurf Medical's Annual General Meeting 2026

In accordance with the decision by the Annual General Meeting, Episurf Medical's Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the Committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. The members of the Nomination Committee shall agree on a chairman/woman of the Committee.

In accordance with the above principles, the Nomination Committee consists of the following four members:

- Ulf Grunander, Chairman of the Board Episurf Medical AB
- Ilija Batljan, representing Health Runner AB
- Hans Bäck, representing Hans Bäck
- Niles Noblitt, representing Sajaco Investments LLC and Pål Ryfors

The members of the Nomination Committee have been appointed based on the ownership structure as of August 31, 2025. The shareholders having appointed members of the Nomination Committee together represent approximately 30 percent of the voting rights for all shares in Episurf Medical.

The Nomination Committee will prepare proposals for the Annual General Meeting 2026 regarding election of chairman/woman and other directors of the board, election of auditor, matters regarding fees, election of chairman/woman of the Annual General Meeting and resolution concerning the Nomination Committee.

Shareholders may contact the Committee with proposals regarding the work of the Committee. Proposals shall be submitted in due time before the Annual General Meeting to ensure that the proposals can be considered. Proposals must be sent to the Chairman of the nomination Committee, via ir@episurf.com.

For more information, please visit the company website: www.episurf.com.

For more information, please contact:

Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.com

About Episurf Medical

Episurf Medical is a newly created real estate company with exposure to a diversified portfolio of real estate assets. The Company aims to deliver expansive value creation through Nordic yielding properties, with a focus on commercial and industrial buildings. The company also has a medical technology business which is based on the individualised implant Episealer® and related surgical instruments, which are used for treating cartilage damage in joints. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, visit the company's website: www.episurf.com.

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 23 February 2026.